Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials

Iram Amanullah,1 Yusra Habib Khan1,2,1, Iqraa Anwar,1 Aqsa Gulzar,1 Tauqeer Hussain Mallhi,2 Ahsan Aftab Raja3

ABSTRACT
The efficacy of vitamin E among patients with non-alcoholic fatty liver disease (NAFLD) is unclear. The current qualitative and quantitative analyses aimed to ascertain the efficacy of vitamin E on clinical outcomes of patients with NAFLD. A systematic search of randomised controlled trials (RCTs) was performed using databases (PubMed, ProQuest, Scopus, EBSCOhost and Ovid) from inception to July 2018. Trials meeting the inclusion criteria were subjected to quality assessment using the Jadad Scoring. All trials meeting the prerequisites information for meta-analysis were subjected to quantitative synthesis of results. Nine RCTs (five in adults and four in children) were included. Four of the five RCTs on adults demonstrated significant improvements in alanine transaminase and other liver function surrogates in patients with NAFLD. On the other hand, only one of the four RCTs conducted on children showed significant improvements in liver functions with the use of vitamin E. Although quantitative synthesis of available data revealed insignificant differences between vitamin E and placebo, still the use of vitamin E improves the level of alanine transaminase and aspartate transaminase by −1.96 and −0.59, with heterogeneity of I²=67% and p=0.001, respectively. Adjuvant vitamin E therapy provides significant biochemical and histological improvements in adult patients with NAFLD, while paediatric patients showed insignificant efficacy compared with placebo. Lifestyle interventions along with vitamin E can provide much better results. Data, including the impact of vitamin E on hepatic histology, are still lacking. Moreover, the short duration of trials limits the conclusion on the safety and efficacy of proposed treatments.

INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is characterised by lipid deposition in the liver parenchyma without significant history of alcohol consumption or other secondary causes.1 Secondary causes may include hepatitis, certain medications and endocrine conditions.2 NAFLD develops in four stages, comprising simple hepatic steatosis and non-alcoholic steatohepatitis (NASH), leading to fibrosis and cirrhosis.3 It has been estimated that approximately one billion individuals worldwide are affected by NAFLD.4 NAFLD is considered the most prevalent liver disease, with an estimated prevalence of around 20%-30% in the Western population.5 NAFLD is mainly associated with obesity, insulin resistance, hypertension and dyslipidaemia.6 Insulin resistance and oxidative stress play a vital role in the progression towards NAFLD in all age groups.6 Oxidative stress occurs as a result of several mechanisms mediated by reactive oxygen species (ROS) in the liver. ROS reacts with the cells, leading to impaired nucleotide and protein synthesis, and is also responsible for inducing apoptosis and cell death, and interferes with the repair mechanisms. These mechanisms in turn may change the physical state of the plasma membrane and cause functional impairments.7

Vitamin E limits membrane injury precipitated by ROS and is considered a promising antioxidant entity for the treatment of NAFLD.8 Other physiological treatments for NAFLD include lifestyle interventions and physical exercise, along with antioxidant therapy.9 Various investigations have been conducted to evaluate the effectiveness of antioxidants for NAFLD.10 Literature suggests a promising role of vitamin E, along with lifestyle modifications, for the treatment of NAFLD. However, existing studies are accompanied by several limitations, which precludes drawing firm conclusions with regard to the efficacy of vitamin E on various clinical outcomes in patients with NAFLD.10

Despite numerous trials conducted to assess the efficacy of vitamin E in patients with NAFLD, there is a dearth of systematic review and meta-analysis drawing firm conclusions from these studies. Sato et al10 in 2015 performed a pool analysis to evaluate the benefits of vitamin E in NAFLD. However, their analysis is limited by several shortcomings. First, the authors have selected only five randomised controlled trials (RCTs) and excluded other trials due to stringent exclusion criteria. Second, their review does not provide qualitative synthesis of all available RCTs. In this context, qualitative and quantitative syntheses of all available trials were performed to quantify the magnitude of treatment response associated with vitamin E in improving alanine transaminase (ALT), aspartate transaminase (AST), body mass index (BMI), steatosis, inflammation, ballooning, fibrosis and histology in patients with NAFLD of all age groups.

MATERIALS AND METHODS
Information sources
Studies were searched by three independent reviewers (IAm, IA, AG) using electronic databases.
Our search applied to PubMed, ProQuest, Scopus, EBSCOhost, Ovid, Journal of American Medical Association (JAMA), ScienceDirect, EMBASE, American Journal of Gastroenterology, Clinical Trial Directories, MEDLINE and Google Scholar from date of database inception to July 2018. The PubMed search strategy served as a reference for the development of search strategies for the remaining databases. The search terms used were “vitamin E”, “nonalcoholic fatty liver disease”, “nonalcoholic steatohepatitis”, “clinical outcomes”, “liver function tests” and “antioxidants”. The search included only published RCTs and was limited to human studies of all genders and age groups.

Inclusion criteria
The inclusion criteria were clinical trials evaluating the effectiveness of vitamin E in patients with NAFLD, regardless of age and gender, by comparing with controls. Trials investigating the impact of vitamin E on at least one treatment outcome (ALT, AST, BMI, steatosis, inflammation, ballooning, fibrosis and histological improvements) were considered for inclusion.

Exclusion criteria
We excluded studies involving (1) patients who are pregnant and with co-existing liver disease, including alcoholic liver disease, autoimmune hepatitis, hepatitis B and hepatitis C; (2) drugs such as valproate, amiiodarone, prednisone and tamoxifen on account of their involvement in the pathogenesis of steatosis; and (3) bariatric surgery, environmental toxins or total parental nutrition, which may cause secondary NAFLD. Moreover, all other studies other than RCTs and those with non-extractable data were excluded from the current review.

Table 1  Jadad Scoring for quality assessment of included trials

<table>
<thead>
<tr>
<th>Trials</th>
<th>Randomisation mentioned</th>
<th>Concealment of randomisation</th>
<th>Blinding</th>
<th>Appropriate blinding method</th>
<th>Reporting of withdrawals</th>
<th>Jadad score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harrison et al</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>5</td>
</tr>
<tr>
<td>Vajro et al</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Unclear</td>
<td>4</td>
</tr>
<tr>
<td>Nobili et al</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>Nobili et al</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Unclear</td>
<td>3</td>
</tr>
<tr>
<td>Sanyal et al</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>4</td>
</tr>
<tr>
<td>Foster et al</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>Yes</td>
<td>Unclear</td>
<td>3</td>
</tr>
<tr>
<td>Lavine et al</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>5</td>
</tr>
<tr>
<td>Hoofnagle et al</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>3</td>
</tr>
<tr>
<td>Aller et al</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>Unclear</td>
<td>Unclear</td>
<td>2</td>
</tr>
</tbody>
</table>
**Table 2  Summary of study characteristics**

<table>
<thead>
<tr>
<th>Author and year of publication</th>
<th>Country name</th>
<th>Study design (RCT)</th>
<th>Study duration including follow-up</th>
<th>Sample size (N)</th>
<th>Baseline characteristics</th>
<th>Dose and frequency of vitamin E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harrison et al, 2003&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Texas, USA</td>
<td>Double-blind</td>
<td>6 months</td>
<td>45 23 22</td>
<td>50–53 44.5</td>
<td>Vitamin E 1000 IU Once daily Placebo Diet + exercise + vitamin C 1000 mg once daily</td>
</tr>
<tr>
<td>Vajro et al, 2004&lt;sup&gt;18&lt;/sup&gt;</td>
<td>Italy</td>
<td>Single-blind</td>
<td>5 months</td>
<td>28 14 14</td>
<td>5.9–14.15 75</td>
<td>Vitamin E 888 IU (2 months) 222 IU (3 months) Once daily Placebo Diet</td>
</tr>
<tr>
<td>Nobili et al, 2006&lt;sup&gt;16&lt;/sup&gt;</td>
<td>Italy</td>
<td>Double-blind</td>
<td>12 months</td>
<td>88 45 43</td>
<td>9–15.5 31.8</td>
<td>Vitamin E 600 IU Once daily Placebo Diet + vitamin C 500 mg once daily</td>
</tr>
<tr>
<td>Nobili et al, 2008&lt;sup&gt;16&lt;/sup&gt;</td>
<td>Italy</td>
<td>Double-blind</td>
<td>24 months&lt;sup&gt;*&lt;/sup&gt;</td>
<td>53 25 28</td>
<td>5.7–18.8 69.8</td>
<td>Vitamin E 600 IU Once daily Placebo Diet + exercise + vitamin C 500 mg once daily</td>
</tr>
<tr>
<td>Sanyal et al, 2010&lt;sup&gt;55&lt;/sup&gt;</td>
<td>USA</td>
<td>Three-arm RCT</td>
<td>120 weeks</td>
<td>247 84 83</td>
<td>Adults above 45 40</td>
<td>Vitamin E 800 IU Once daily Placebo Pioglitazone 30 mg once daily</td>
</tr>
<tr>
<td>Lavine et al, 2011&lt;sup&gt;16&lt;/sup&gt;</td>
<td>USA</td>
<td>Three-arm RCT</td>
<td>120 weeks</td>
<td>173 58 58</td>
<td>8–17 81</td>
<td>Vitamin E 800 IU Once daily Placebo Dietary restriction + exercise + metformin 1000 mg once daily</td>
</tr>
<tr>
<td>Foster et al, 2011&lt;sup&gt;13&lt;/sup&gt;</td>
<td>USA</td>
<td>Double-blind</td>
<td>4 years</td>
<td>80 44 36</td>
<td>50–70 77.5</td>
<td>Vitamin E 1000 IU Once daily Placebo Vitamin C 1000 mg once daily, atorvastatin 20 mg once daily, aspirin 81 mg</td>
</tr>
<tr>
<td>Hoofnagle et al, 2013&lt;sup&gt;14&lt;/sup&gt;</td>
<td>USA</td>
<td>Double-blind</td>
<td>120 weeks</td>
<td>139 71 68</td>
<td>19–71 42</td>
<td>Vitamin E 800 IU Once daily Placebo Pioglitazone 30 mg</td>
</tr>
<tr>
<td>Aller et al, 2015&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Spain</td>
<td>Three-arm RCT</td>
<td>3 months</td>
<td>36 18 18</td>
<td>18–67 61.1</td>
<td>Vitamin E 80 IU Once daily Placebo Hypocaloric diet 1520 kcal and aerobic exercise at least 4 times a week 60 min each + silymarin 540.3 mg twice daily</td>
</tr>
</tbody>
</table>

<sup>*</sup>Open-label extension of a previous study Nobili et al. IU, international unit; RCT, randomised controlled trial.
**Data extraction**

Three researchers independently screened all titles and abstracts retrieved from the electronic databases using the defined selection criteria. Then, the full text of each potentially eligible article was obtained and screened independently by the researchers to further assess its suitability for inclusion in this review. All the results were collected, compiled and compared. Any conflict or deviation was solved through mutual consultation and concurrence.

**Study selection**

A total of 147 studies were initially identified and considered potentially relevant. Of these, 111 studies did not meet the inclusion criteria. Twenty-seven studies were evaluated in detail to determine whether they described the role of vitamin E in NAFLD. Subject to further exclusion as described in figure 1, nine RCTs meeting the selection criteria were considered for the current review and analysis. Figure 1 illustrates the Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram of study selection.

**Quality assessment**

Evaluation and scoring for RCTs were based on the Jadad Scoring System.13 The Jadad scale, sometimes known as Jadad scoring or the Oxford Quality Scoring System, is a procedure used to independently assess the methodological quality of clinical trials. The JSC scores studies from 0 to 5, where a high score indicates good-quality study. The components of JSC include randomisation (2 points), blinding (2 points) and account of withdrawals (1 point). The overall Jadad score for each included RCT is described in table 1.

**Quantitative synthesis**

For absolute values of ALT, ALT, BMI, steatosis, lobular inflammation, hepatocellular ballooning, fibrosis and histological improvement at last visit on treatment, we estimated the pooled mean differences between the two treatment groups (vitamin E and control) and the 95% CI. Only studies having the required mean values were included for pool analysis. All statistical analyses were done using the Review Manager V.5.2 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). The I² statistic was used to assess heterogeneity. A fixed-effect model was used when I² was <50%, which indicated heterogeneity. If I² was >50%, a random-effects model was used after consideration of the potential sources of heterogeneity.

**RESULTS**

A total of nine RCTs published in 2003–2015 were included in the current review. Of these, five trials were from the USA, three from Italy and only one trial was conducted in Spain. A summary of the characteristics of the included trials is described in table 2.

**Descriptive summary of included trials**

All trials included 889 patients with the mean age ranging from 9.88±3.97 to 59.40±6.0 years. Five trials included adult patients as the study population,1 12–15 while the remaining four studies included children.6 16–18 The study duration of trials varied from 6 months to 4 years, including the follow-up period. Table 2 demonstrates the variability of the included trials.

**Description of intervention**

Vitamin E was the intervention in all RCTs and compared with at least one control group. There was a single-blind RCT...
comparing vitamin E with placebo. Two studies had three-arm design, one comparing vitamin E with metformin and placebo, and the other compared vitamin E with silymarin and placebo. Moreover, all remaining six RCTs were double-blind, in which vitamin E therapy. However, other outcomes were not improved in these four trials conducted on children (table 3).

It must be noted that the level of significance varies in some trials. Sanyal et al15 considered p<0.025 as significant and Lavine et al14 made significance at p<0.01, while all other trials estimated significance at p<0.05.

Effect of adjuvant vitamin E on ALT

The effect of adjuvant vitamin E on ALT was demonstrated in all RCTs included in the review (table 4).

RCTs conducted on adults

The effect of adjuvant vitamin E on ALT was demonstrated in all five trials on adult population. Hoofnagle et al14 showed more significant drop in ALT values in the intervention group (IG) compared with the control group (CG). In contrast, Harrison et al12 showed more significant drop in ALT values in CG than in IG. Sanyal et al15 and Aller et al17 showed a significant drop in ALT values in both IG and CG, but the drop was much prominent in IG. Foster et al13 showed insignificant improvements in ALT levels.

RCTs conducted on children

The effect of adjuvant vitamin E on ALT was demonstrated in all four trials conducted on children. Nobili et al16 showed more significant drop in ALT values in IG compared with CG. Lavine et al14, Nobili et al17 and Vajro et al18 showed insignificant improvements in ALT levels.

Effect of adjuvant vitamin E on AST

The effect of adjuvant vitamin E on AST was demonstrated in seven trials (table 4).

---

**Table 4** Impact of vitamin E on ALT, AST, BMI and steatosis score in trials

<table>
<thead>
<tr>
<th>Author and year</th>
<th>Outcomes with respect to control and intervention group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ALT (U/L)</td>
</tr>
<tr>
<td></td>
<td>Intervention</td>
</tr>
<tr>
<td>Harrison et al, 200313</td>
<td>−12.3</td>
</tr>
<tr>
<td>Vajro et al, 200418</td>
<td>−31.90†</td>
</tr>
<tr>
<td>Nobili et al, 20066</td>
<td>−36.35</td>
</tr>
<tr>
<td>Nobili et al, 200818</td>
<td>−31</td>
</tr>
<tr>
<td>Sanyal et al, 201017</td>
<td>−37</td>
</tr>
<tr>
<td>Lavine et al, 201114</td>
<td>−48.3</td>
</tr>
<tr>
<td>Foster et al, 201113</td>
<td>*</td>
</tr>
<tr>
<td>Hoofnagle et al, 201314</td>
<td>−21.6</td>
</tr>
<tr>
<td>Aller et al, 201515</td>
<td>−3.7</td>
</tr>
</tbody>
</table>

(−) Improvement in the outcome (mean response value – mean baseline value).
*Non-significant.
†Evaluation at month 2; this p value indicates difference between control and intervention group.
‡Evaluation at month 5; this p value indicates difference between control and intervention group.
§Steatosis was present in all biopsies, mostly macrovesicular, but frequently associated with microvesicular steatosis.
*Significant improvement.

ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; NR, not reported.

**Description of cointervention**

Diet and exercise were cointerventions in four trials. In two trials, diet was the only cointervention, applied on both the intervention and the control group. Three trials included only vitamin E and control group, without any cointervention. The cointerventions are described in table 2.

**Effect of vitamin E on outcomes**

In adult patients with NAFLD, adjuvant vitamin E therapy significantly improved the biochemical and histological parameters of the liver. Four out of five trials among adults showed significant improvements in ALT. These trials also demonstrated significant improvements in other outcomes.

Among trials conducted on children, Nobili et al16 showed improvements in ALT, AST and BMI, and Lavine et al14 demonstrated improved ballooning scores with the use of adjuvant vitamin E therapy. However, other outcomes were not improved in these four trials conducted on children (table 3).
### Table 5  Impact of vitamin E on inflammation score, ballooning score, fibrosis score and histological improvement

<table>
<thead>
<tr>
<th>Author and year</th>
<th>Inflammation score</th>
<th>Ballooning score</th>
<th>Fibrosis score</th>
<th>Histological improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intervention</td>
<td>Control</td>
<td>P value</td>
<td>Intervention</td>
</tr>
<tr>
<td>Harrison et al, 2003</td>
<td>*</td>
<td>*</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Vajro et al, 2004</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Nobili et al, 2005</td>
<td>†</td>
<td>†</td>
<td>NR</td>
<td>†</td>
</tr>
<tr>
<td>Nobili et al, 2007</td>
<td>0</td>
<td>−1</td>
<td>0.7</td>
<td>2</td>
</tr>
<tr>
<td>Sanjai et al, 2010</td>
<td>−0.972</td>
<td>−0.56</td>
<td>0.02</td>
<td>−0.65</td>
</tr>
<tr>
<td>Lavine et al, 2011</td>
<td>−0.352</td>
<td>−0.34</td>
<td>0.89</td>
<td>−0.22</td>
</tr>
<tr>
<td>Foster et al, 2011</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Hoofnagle et al, 2013</td>
<td>−1.1</td>
<td>−0.5</td>
<td>Vitamin E=0.01 Placebo=0.14</td>
<td>−0.8</td>
</tr>
</tbody>
</table>

(−) Improvement in the outcome (mean response value − mean baseline value).

* Non-significant improvement.

Inflammation was present in 77 children. Hepatocyte ballooning was present in 46 patients. Increased fibrosis was noted in 54 but mostly of mild (stage 1) severity, with only five children showing septal fibrosis (stage 3).

NR, not reported.
RCTs conducted on children
The effect of adjuvant vitamin E on inflammation was demonstrated in all four trials. All the trials did not show any significant improvements in IG compared with CG with the use of vitamin E.6 16–18

Effect of adjuvant vitamin E on ballooning score
The effect of adjuvant vitamin E on ballooning was demonstrated in five out of nine trials (table 5).

RCTs conducted on adults
The effect of adjuvant vitamin E on ballooning score was demonstrated in two trials. Sanyal et al15 and Hoofnagle et al14 showed a minute drop of ballooning score in IG compared with CG.

RCTs conducted on children
The effect of adjuvant vitamin E on ballooning score was demonstrated in three of four trials conducted on children. Lavine et al6 showed a minute drop of ballooning score in IG compared with CG. On the other hand, Nobili et al16 and Nobili et al17 showed insignificant improvements.

Effect of adjuvant vitamin E on fibrosis score
The effect of adjuvant vitamin E on fibrosis was demonstrated in eight trials (table 5).

RCTs conducted on adults
The effect of adjuvant vitamin E on fibrosis score was demonstrated in four trials. Harrison et al12 showed significant improvement in fibrosis score in IG compared with CG. Sanyal et al15,16 Hoofnagle et al14 and Aller et al1 showed insignificant improvements in fibrosis score in IG compared with CG.

RCTs conducted on children
The effect of adjuvant vitamin E on histological improvement was demonstrated in three trials. All RCTs showed insignificant histological improvements in IG compared with CG.6 16–18

The quantitative effect of vitamin E versus placebo on six outcomes is described in figures 2 and 3. The impact of vitamin E on ALT levels was analysed through five studies that fell in our inclusion criteria. Vitamin E was able to reduce the ALT levels by −1.96 (95% CI −9.24 to 5.31; p=0.60) in comparison with placebo. The level of heterogeneity was moderately high (I²=67%). Moreover, vitamin E was able to reduce the AST counts by −11.39 (95% CI −37.15 to 13.68; p=0.37) when compared with placebo. The level of heterogeneity was high (I²=99%); thereby, the study of Lavine et al6 was omitted given its effect size in comparison with other studies. Subsequently, the level of heterogeneity was reduced (I²=0%) along with 95% CI (−0.59 (−4.18 to 3.01); p=0.75) (figure 2).

Figure 2  Impact of vitamin E on ALT and AST. ALT, alanine transaminase; AST, aspartate transaminase; VIT E, vitamin E; IV, Inverse Variance.
Altogether four studies were analysed to observe the impact of vitamin E on BMI. Our results suggest that vitamin E was able to reduce BMI by $0.07$ (95% CI $-0.74$ to $0.60$; $p=0.84$) in comparison with placebo. The level of heterogeneity was low ($I^2=31\%$). Two studies were analysed for the impact of vitamin E on ballooning, which suggested that vitamin E did not have any significant impact on ballooning score ($0.69$ (95% CI $-1.86$ to $3.23$); $p=0.60$). The level of heterogeneity was high ($I^2=99\%$). Furthermore, vitamin E was able to reduce the fibrosis score by $-0.52$ (95% CI $-1.40$ to $3.62$; $p=0.24$) with high level of heterogeneity ($I^2=94\%$). Vitamin E improved histological findings in comparison with placebo by $-0.72$ (95% CI $-1.75$ to $0.3$; $p=0.17$) with moderate level of heterogeneity ($I^2=68\%$) among the studies (figure 3).

DISCUSSION
NAFLD is closely related to metabolic syndrome. It can be more acute, and progressive disease may lead to the development of cirrhosis. Lifestyle modifications, including diet and weight reduction, are the mainstay of management for patients with NAFLD. However, patients hardly achieve their lifestyle goals, and pharmacological treatment is usually considered to achieve optimum outcomes. Although data on the pathogenesis of NAFLD are scarce, oxidative stress is observed to be a major contributing factor to the evolution and progression of NAFLD among patients.

Vitamin E is considered a chain-breaking antioxidant in free radical reactions such as lipid peroxidation. It forms complexes with the electrons of the free radicals and provides protection against lipid peroxidation. In this context, vitamin E is considered an effective entity against ROS and protects against cytokine-transforming growth factor beta 1 (TGF-β1)-related liver fibrosis. The association of NAFLD with insulin resistance, obesity and hyperlipidaemia is well documented. Oxidative stress, endotoxin-induced cytokine release and metabolic changes contribute to the progression of the disease. Li et al in 2015 concluded that vitamin E improves the integrity of the liver by reducing response to membrane transporter involved in fatty acid uptake.

Numerous observational cohort and case–control studies have been performed to determine the effect of vitamin E on NAFLD, but the findings are not conclusive. In 2011, Erhardt et al compared the antioxidant level of patients with NAFLD with the control, and concluded decreased level of tocopherols in NAFLD. Sanyal et al revealed that vitamin E is superior over placebo and significantly improves hepatic inflammation, steatosis and hepatic cellular ballooning in NAFLD, but the improvement in fibrosis was not evident. Similarly Nobili et al did not find any significant change
in fibrosis.\textsuperscript{17} However, the efficacy of vitamin E for the improvement in fibrosis score and histological responses has been evident in available data.\textsuperscript{26}

Vitamin E significantly improves ALT, AST, histological changes, steatosis, inflammation and hepatocellular ballooning.\textsuperscript{10} Aller \textit{et al.}\textsuperscript{14} found that the combination therapy of vitamin E and silymarin shows significant improvements in ALT and AST, which might be attributed to the reduction of enzyme dispersion in extracellular medium and restoration of normal membrane permeability of the liver. The impact of vitamin E has also been evaluated in one meta-analysis which illustrated that vitamin E therapy causes significant improvements in ALT/AST levels.\textsuperscript{19}

Hoofnagle \textit{et al.}\textsuperscript{14} in 2010 concluded that vitamin E improved ALT and that histological responses were more evident in patients with NASH who lost weight.\textsuperscript{20} In 2017, Zöhrer \textit{et al.}\textsuperscript{21} illustrated that a combination therapy of docosahexaenoic acid–choline–vitamin E has shown significant improvements in ALT, steatosis and ballooning among paediatric patients with NASH. It was the first study conducted on children with NASH concluding the efficacy of three nutritional supplements in combination with diet and exercise.\textsuperscript{27}

Although the qualitative analysis in the current review describes the promising impact of vitamin E on almost all clinical outcomes of patients with NAFLD, pool analysis revealed that vitamin E therapy shows different effects on ALT and AST only. Meta-analysis showed improvements in BMI, ballooning, fibrosis and histology, but such improvements were not significant to draw a firm conclusion. These discrepancies in the results of pool analysis might be attributed to several reasons. Most of the studies conducted on adult population do not have values of mean and SD, which are prerequisites to conduct an analysis. Moreover, there were wide variations in demographic profiles of recruited patients, dose of vitamin E, nature of interventions and durations of follow-up in the included trials. It must be noted that the meta-analysis is primarily limited to the trials conducted on children, and qualitative findings of these trials correspond to the quantitative results that vitamin E therapy has insignificant impact on most of the clinical outcomes of patients with NAFLD. These results indicate the dire need to conduct larger trials by using fixed dose and duration of therapy among variable groups of patients so findings could be uniformly compared and standardised across the literature.

The impact of vitamin E on liver enzymes was mostly studied in adult population, while data on children are quite limited. These findings underscore the need for further studies concentrating on the histological endpoints among children. Vitamin E also possesses some anti-inflammatory properties. Evidence has been shown that overproduction of proinflammatory cytokines is reduced by vitamin E.\textsuperscript{22} However, high-dose vitamin E can lead to an increased risk of bleeding.\textsuperscript{23} Moreover, daily high dose of vitamin E can increase the risk of prostate cancer.\textsuperscript{24} Unfortunately, these trials did not study any safety profile of vitamin E. There is a dire need to investigate the risks of vitamin E therapy in both children and adults to establish safety profile.

**LIMITATIONS**

There was a lack of justification in outcomes of some included studies. Most of the studies were conducted on specific age groups, either adults or children. The methodological quality and sample size of studies were limited. Based on the JSC, four out of nine studies were evaluated as low quality.\textsuperscript{15} vitamin E formulation and dosage variations among studies led to difficulty in investigating the effects of different dosage regimens. Subject to these variations, pool analysis of data was not favouring the qualitative findings of the trials.

Despite mentioned limitations, all studies were RCTs, so reliable inferences improved internal causality. The current review included trials of both children and adults, hence providing detailed insight into the benefits of therapy in both age groups. Since all participants were proven histological patients with NAFLD, misclassification bias is minimised. Last but not least, the current review examined all possible outcomes related to NAFLD and the impact of vitamin E on them.

**Main messages**

- Adjuvant vitamin E therapy provides significant biochemical and histological improvements in adult patients with non-alcoholic fatty liver disease (NAFLD).
- The effect of vitamin E therapy on liver functioning was not significant among the paediatric population.
- The findings of the current review are limited by the short duration of trials and scarcity of safety and efficacy data of proposed treatments.
- The proven interventions in children with NAFLD are lifestyle interventions, including dietary modifications and physical exercise, that result in significant improvements in hepatic functioning.

**Key references**


**Current research questions**

- Does vitamin E therapy improve outcomes among patients with non-alcoholic fatty liver disease?
- On which outcomes did vitamin E show marked improvement?
- Is the impact of vitamin E equally distributed in all age groups?
- Is adjuvant vitamin E safe for adult and paediatric population?
Review

Self assessment questions

1. What factor(s) associates with the progression of non-alcoholic fatty liver disease (NAFLD)?
   A. Obesity.
   B. Insulin resistance.
   C. Hypertension.
   D. Dyslipidaemia.
   E. All of them.

2. The oxidative stress in NAFLD is primarily associated with
   A. Vitamin E.
   B. Reactive oxygen species (ROS).
   C. Glutathione.
   D. Both A and C.

3. The primary lifestyle modification with vitamin E therapy which reduces disease progression in NAFLD is
   A. Low protein diet.
   B. Reducing weight.
   C. High protein diet.
   D. Both A and C.

4. The impact of vitamin E therapy on liver functioning is not remarkable in which group of patients?
   A. Children.
   B. Adults.
   C. Elderly.
   D. Women.

5. The primary role of vitamin E during the management of NAFLD is
   A. Oxidant potential.
   B. Antioxidant activity.
   C. Anti-ROS activity.
   D. Both B and C.

CONCLUSION
The findings from the current review suggest that adjuvant vitamin E therapy provides significant biochemical and histological improvements in adult patients with NAFLD. The association of vitamin E therapy with normalisation of serum biochemical parameters and improved hepatic histology was not significantly observed in children. Moreover, the short duration of trials also limits the conclusion on the safety and efficacy of proposed treatments. This qualitative and quantitative review might help to revise the practice guidelines on the management of NAFLD by supplying high level of evidence.

FUTURE RECOMMENDATIONS
This review underscores the need for carefully controlled RCTs with longer duration and adequate power, particularly in children. Moreover, prospective trials must consider the appropriateness of dosage regimen so that future guidelines could be developed based on their findings.

Correction notice This paper has been corrected since it appeared Online First. Footnote 1 has been removed from table 5.

Acknowledgements We greatly acknowledge the support of the Statistical Department of GC University Faisalabad for providing assistance during analysis.

Contributors YHK conceptualised the plan for the current study. IAM, IAN and AG did the literature search, screening and data extraction, and drafted the manuscript. AAR performed the meta-analysis for the included studies. YHK assisted in interpreting the results. YHK and THM assessed the data quality and approved the final version of the manuscript for submission. All authors have critically reviewed the manuscript. YHK is the guarantor.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

ORCID iD Yusra Habib Khan http://orcid.org/0000-0002-9479-6147

REFERENCES


Review


Answers

1. E. All of them.
2. B. Reactive oxygen species.
3. B. Reducing weight.
5. D. Both B and C.